

Disclaimer: The following document is a translation of a press release prepared in Japanese. The Japanese version is the original version and can be found on the company's website: <http://www.santen.co.jp>. In case of any discrepancy between the Japanese and English versions, the Japanese version will prevail.

August 3, 2015

Notice of Completion of the Transfer of Anti-Rheumatic Pharmaceutical Business to AYUMI Pharmaceutical Corporation

August 3, 2015, Osaka, Japan – Santen Pharmaceutical Co., Ltd. (“Santen”) hereby notifies that the simplified company split relating to the transfer of Santen’s Anti-Rheumatic Pharmaceutical business to AYUMI Pharmaceutical Corporation (formerly Hyperion Pharma Co., Ltd.) announced in the May 12, 2015 “Announcement of Santen’s Assignment of its Anti-Rheumatic Pharmaceuticals Business to Hyperion Pharma (SPC: Special Purpose Company) through Simplified Company Split Method” is effectuated today. AYUMI Pharmaceutical Corporation changed its name from Hyperion Pharma Co., Ltd. on June 2, 2015.

As the impact of this event to Santen’s financial performance is already reflected in the forecast announced on May 12, 2015, no further adjustments to the annual forecast for this term are expected.

About Santen

As a specialty company dedicated to the ophthalmic field, Santen carries out research, development, sales, and marketing of pharmaceuticals. The company has its bases in about 20 countries and delivers products in more than 70 countries. In Japan, Santen holds the No. 1 share in the prescription ophthalmic pharmaceutical market. As a leading company in the field of ophthalmology, Santen aims to contribute to society by supplying valuable products and services to satisfy unmet medical needs. For more details, please see Santen’s website (www.santen.com).

Santen Forward-looking Statements

Information provided in this press release contains so-called “Forward-looking Statements”. The realizations of these forecasts are subject to risk and uncertainty from various sources. Therefore, please note that the actual results may differ significantly from the forecasts. Business performance and financial condition are subject to the effects of change in regulations made by the governments of Japan and other nations concerning medical insurance, drug pricing and other systems, and to fluctuations in market variables such as interest rates and foreign exchange rates.

Contact

Takashi Hibi, General Manager
Corporate Communication Group
Santen Pharmaceutical Co., Ltd.
E-mail: ir@santen.co.jp
Tel: +81-6-4802-9360